Jen-Chih Tseng

Title: Innovations in Cancer Immunotherapy by Jen-Chih Tseng

Introduction

Jen-Chih Tseng is a prominent inventor based in Zhunan, Taiwan. He has made significant contributions to the field of cancer immunotherapy, focusing on enhancing treatment efficacy through innovative approaches. His work is particularly relevant in the context of immune checkpoint blockade therapies.

Latest Patents

Jen-Chih Tseng holds a patent for "CpG-oligodeoxynucleotide compounds in combination with immune modulators for cancer immunotherapy." This invention discloses a combinational therapy aimed at enhancing the efficacy of immune checkpoint blockade for tumors characterized by an immune suppressive microenvironment. The combination therapy involves the use of immune checkpoint inhibitors alongside CpG-oligodeoxynucleotides to treat cancer effectively.

Career Highlights

Tseng is affiliated with the National Health Research Institutes, where he conducts research and develops innovative therapeutic strategies. His work has garnered attention for its potential to improve cancer treatment outcomes.

Collaborations

Some of his notable coworkers include Tsung-Hsien Chuang and Jing-Xing Yang, who collaborate with him on various research projects aimed at advancing cancer therapies.

Conclusion

Jen-Chih Tseng's contributions to cancer immunotherapy through his innovative patent highlight the importance of combining different therapeutic approaches to enhance treatment efficacy. His work continues to pave the way for advancements in cancer treatment strategies.